Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
Before the FDA’s upcoming approval decision for Eisai’s Alzheimer’s treatment, lecanemab, the company released Phase 3 study data from the confirmatory CLARITY AD trial. The release comes just days after reports of a second patient death in the trial, which Eisai addressed, saying both deaths resulted from substantial comorbidities and risk factors, not from lecanemab.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02